Literature DB >> 9230793

In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia.

J K Baird1, I Wiady, D J Fryauff, M A Sutanihardja, B Leksana, H Widjaya, B Subianto.   

Abstract

A survey of resistance to chloroquine by Plasmodium vivax and P. falciparum was conducted during May 1995 at three mesoendemic villages 30 km southeast of Nabire, near the central northern coast of Irian Jaya, Indonesia. The prevalence of malaria at Urusumu (n = 157), Margajaya (n = 573), and Topo (n = 199) was 18%. 9%, and 9%, respectively, with spleen rates among children of 79%, 10%, and 27%. Infected patients among those screened formed a study population of 64 subjects eligible for a 28-day in vivo test of resistance to chloroquine. Sixty-three patients successfully completed the test; 45 males and 18 females 1-60 years of age, of whom 29 were Javanese transmigrants of five years residence in Irian Jaya and 34 were native to Irian Jaya. The seven-day day cumulative incidence of therapeutic failure for P. vivax and P. falciparum was 15% (n = 34) and 30% (n = 37). The 14- and 28-day estimates of cumulative incidence were 45% and 64% for P. vivax and 58% and 89% for P. falciparum. Almost all recurrences appeared in the face of ordinarily effective levels of chloroquine and its major metabolite, desethylchloroquine, in whole blood (> or = 100 ng/ml). Four infections by P. malariae in subjects enrolled in this study cleared by day 2 and none reappeared within 28 days. Chloroquine no longer provides effective therapy for falciparum or vivax malaria along the northern coast of Irian Jaya, Indonesia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9230793     DOI: 10.4269/ajtmh.1997.56.627

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  28 in total

Review 1.  History, dynamics, and public health importance of malaria parasite resistance.

Authors:  Ambrose O Talisuna; Peter Bloland; Umberto D'Alessandro
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

Review 2.  Chloroquine resistance in Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

3.  In vitro anti-malarial drug susceptibility of temperate Plasmodium vivax from central China.

Authors:  Feng Lu; Qi Gao; Kesinee Chotivanich; Hui Xia; Jun Cao; Rachanee Udomsangpetch; Liwang Cui; Jetsumon Sattabongkot
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

Review 4.  Resistance to therapies for infection by Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

5.  Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia.

Authors:  Inge Sutanto; Bagus Tjahjono; Hasan Basri; W Robert Taylor; Fauziah A Putri; Rizka A Meilia; Rianto Setiabudy; Siti Nurleila; Lenny L Ekawati; Iqbal Elyazar; Jeremy Farrar; Herawati Sudoyo; J Kevin Baird
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

6.  High-dose primaquine regimens against relapse of Plasmodium vivax malaria.

Authors:  Srivicha Krudsood; Noppadon Tangpukdee; Polrat Wilairatana; Nantaporn Phophak; J Kevin Baird; Gary M Brittenham; Sornchai Looareesuwan
Journal:  Am J Trop Med Hyg       Date:  2008-05       Impact factor: 2.345

7.  Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand.

Authors:  Udomsak Silachamroon; Srivicha Krudsood; Sombat Treeprasertsuk; Polrat Wilairatana; Kobsiri Chalearmrult; Hla Yin Mint; Pannamas Maneekan; Nicholas J White; Victor R Gourdeuk; Gary M Brittenham; Sornchai Looareesuwan
Journal:  Am J Trop Med Hyg       Date:  2003-07       Impact factor: 2.345

8.  Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.

Authors:  Ghulam Rahim Awab; Sasithon Pukrittayakamee; Mallika Imwong; Arjen M Dondorp; Charles J Woodrow; Sue Jean Lee; Nicholas P J Day; Pratap Singhasivanon; Nicholas J White; Faizullah Kaker
Journal:  Malar J       Date:  2010-04-21       Impact factor: 2.979

9.  Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia.

Authors:  Inge Sutanto; Dedeh Endawati; Liem Hui Ling; Ferdinand Laihad; Rianto Setiabudy; J Kevin Baird
Journal:  Malar J       Date:  2010-02-12       Impact factor: 2.979

10.  Chloroquine-resistant Plasmodium vivax, Brazilian Amazon.

Authors:  Franklin Simoes de Santana Filho; Ana Ruth de Lima Arcanjo; Yonne Melo Chehuan; Monica Regina Costa; Flor Ernestina Martinez-Espinosa; Jose Luis Vieira; Maria das Graças Vale Barbosa; Wilson Duarte Alecrim; Maria das Graças Costa Alecrim
Journal:  Emerg Infect Dis       Date:  2007-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.